Wedbush Maintains Outperform Rating on Beam Therapeutics, Sets $28 Target
Wedbush maintained its Outperform rating on Beam Therapeutics and a $28 price target. The target implies 12.4% upside from the October 27 close of $24.90.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.